Cargando…

The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology

Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zutautas, Katherine B., Sisnett, Danielle J., Miller, Jessica E., Lingegowda, Harshavardhan, Childs, Timothy, Bougie, Olga, Lessey, Bruce A., Tayade, Chandrakant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076726/
https://www.ncbi.nlm.nih.gov/pubmed/37033980
http://dx.doi.org/10.3389/fimmu.2023.1089098
_version_ 1785020196741709824
author Zutautas, Katherine B.
Sisnett, Danielle J.
Miller, Jessica E.
Lingegowda, Harshavardhan
Childs, Timothy
Bougie, Olga
Lessey, Bruce A.
Tayade, Chandrakant
author_facet Zutautas, Katherine B.
Sisnett, Danielle J.
Miller, Jessica E.
Lingegowda, Harshavardhan
Childs, Timothy
Bougie, Olga
Lessey, Bruce A.
Tayade, Chandrakant
author_sort Zutautas, Katherine B.
collection PubMed
description Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation, and infertility. Alterations to Leukemia Inhibitory Factor (LIF), a cytokine produced by the luminal and glandular epithelium of the endometrium that is imperative for successful pregnancy, have been postulated to contribute to infertility. Conditions such as recurrent implantation failure, unexplained infertility, and infertility associated diseases such as adenomyosis and endometriosis, have demonstrated reduced LIF production in the endometrium of infertile patients compared to fertile counterparts. While this highlights the potential involvement of LIF in infertility, LIF is a multifaceted cytokine which plays additional roles in the maintenance of cell stemness and immunomodulation. Thus, we sought to explore the implications of LIF production within ectopic lesions on endometriosis pathophysiology. Through immunohistochemistry of an endometrioma tissue microarray and ELISA of tissue protein extract and peritoneal fluid samples, we identify LIF protein expression in the ectopic lesion microenvironment. Targeted RT qPCR for LIF and associated signaling transcripts, identify LIF to be significantly downregulated in the ectopic tissue compared to eutopic and control while its receptor, LIFR, is upregulated, highlighting a discordance in ectopic protein and mRNA LIF expression. In vitro treatment of endometriosis representative cell lines (12Z and hESC) with LIF increased production of immune-recruiting cytokines (MCP-1, MCP-3) and the angiogenic factor, VEGF, as well as stimulated tube formation in human umbilical vein endothelial cells (HUVECs). Finally, LIF treatment in a syngeneic mouse model of endometriosis induced both local and peripheral alterations to immune cell phenotypes, ultimately reducing immunoregulatory CD206(+) small peritoneal macrophages and T regulatory cells. These findings suggest that LIF is present in the ectopic lesions of endometriosis patients and could be contributing to lesion vascularization and immunomodulation.
format Online
Article
Text
id pubmed-10076726
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100767262023-04-07 The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology Zutautas, Katherine B. Sisnett, Danielle J. Miller, Jessica E. Lingegowda, Harshavardhan Childs, Timothy Bougie, Olga Lessey, Bruce A. Tayade, Chandrakant Front Immunol Immunology Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation, and infertility. Alterations to Leukemia Inhibitory Factor (LIF), a cytokine produced by the luminal and glandular epithelium of the endometrium that is imperative for successful pregnancy, have been postulated to contribute to infertility. Conditions such as recurrent implantation failure, unexplained infertility, and infertility associated diseases such as adenomyosis and endometriosis, have demonstrated reduced LIF production in the endometrium of infertile patients compared to fertile counterparts. While this highlights the potential involvement of LIF in infertility, LIF is a multifaceted cytokine which plays additional roles in the maintenance of cell stemness and immunomodulation. Thus, we sought to explore the implications of LIF production within ectopic lesions on endometriosis pathophysiology. Through immunohistochemistry of an endometrioma tissue microarray and ELISA of tissue protein extract and peritoneal fluid samples, we identify LIF protein expression in the ectopic lesion microenvironment. Targeted RT qPCR for LIF and associated signaling transcripts, identify LIF to be significantly downregulated in the ectopic tissue compared to eutopic and control while its receptor, LIFR, is upregulated, highlighting a discordance in ectopic protein and mRNA LIF expression. In vitro treatment of endometriosis representative cell lines (12Z and hESC) with LIF increased production of immune-recruiting cytokines (MCP-1, MCP-3) and the angiogenic factor, VEGF, as well as stimulated tube formation in human umbilical vein endothelial cells (HUVECs). Finally, LIF treatment in a syngeneic mouse model of endometriosis induced both local and peripheral alterations to immune cell phenotypes, ultimately reducing immunoregulatory CD206(+) small peritoneal macrophages and T regulatory cells. These findings suggest that LIF is present in the ectopic lesions of endometriosis patients and could be contributing to lesion vascularization and immunomodulation. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076726/ /pubmed/37033980 http://dx.doi.org/10.3389/fimmu.2023.1089098 Text en Copyright © 2023 Zutautas, Sisnett, Miller, Lingegowda, Childs, Bougie, Lessey and Tayade https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zutautas, Katherine B.
Sisnett, Danielle J.
Miller, Jessica E.
Lingegowda, Harshavardhan
Childs, Timothy
Bougie, Olga
Lessey, Bruce A.
Tayade, Chandrakant
The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title_full The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title_fullStr The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title_full_unstemmed The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title_short The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
title_sort dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076726/
https://www.ncbi.nlm.nih.gov/pubmed/37033980
http://dx.doi.org/10.3389/fimmu.2023.1089098
work_keys_str_mv AT zutautaskatherineb thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT sisnettdaniellej thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT millerjessicae thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT lingegowdaharshavardhan thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT childstimothy thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT bougieolga thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT lesseybrucea thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT tayadechandrakant thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT zutautaskatherineb dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT sisnettdaniellej dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT millerjessicae dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT lingegowdaharshavardhan dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT childstimothy dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT bougieolga dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT lesseybrucea dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology
AT tayadechandrakant dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology